Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum
Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved..
Synthetic glucocorticoids (sGCs) such as dexamethasone (DEX), while used to mitigate inflammation and disease progression in premature infants with severe bronchopulmonary dysplasia (BPD), are also associated with significant adverse neurologic effects such as reductions in myelination and abnormalities in neuroanatomical development. Ciclesonide (CIC) is a sGC prodrug approved for asthma treatment that exhibits limited systemic side effects. Carboxylesterases enriched in the lower airways convert CIC to the glucocorticoid receptor (GR) agonist des-CIC. We therefore examined whether CIC would likewise activate GR in neonatal lung but have limited adverse extra-pulmonary effects, particularly in the developing brain. Neonatal rats were administered subcutaneous injections of CIC, DEX or vehicle from postnatal days 1-5 (PND1-PND5). Systemic effects linked to DEX exposure, including reduced body and brain weight, were not observed in CIC treated neonates. Furthermore, CIC did not trigger the long-lasting reduction in myelin basic protein expression in the cerebral cortex nor cerebellar size caused by neonatal DEX exposure. Conversely, DEX and CIC were both effective at inducing the expression of select GR target genes in neonatal lung, including those implicated in lung-protective and anti-inflammatory effects. Thus, CIC is a promising, novel candidate drug to treat or prevent BPD in neonates given its activation of GR in neonatal lung and limited adverse neurodevelopmental effects. Furthermore, since sGCs such as DEX administered to pregnant women in pre-term labor can adversely affect fetal brain development, the neurological-sparing properties of CIC, make it an attractive alternative for DEX to treat pregnant women severely ill with respiratory illness, such as with asthma exacerbations or COVID-19 infections.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Neurobiology of disease - 156(2021) vom: 01. Aug., Seite 105422 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jaumotte, Juliann D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.07.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nbd.2021.105422 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32674018X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32674018X | ||
| 003 | DE-627 | ||
| 005 | 20231225195241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nbd.2021.105422 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1089.xml |
| 035 | |a (DE-627)NLM32674018X | ||
| 035 | |a (NLM)34126164 | ||
| 035 | |a (PII)S0969-9961(21)00171-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jaumotte, Juliann D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ciclesonide activates glucocorticoid signaling in neonatal rat lung but does not trigger adverse effects in the cortex and cerebellum |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.07.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a Synthetic glucocorticoids (sGCs) such as dexamethasone (DEX), while used to mitigate inflammation and disease progression in premature infants with severe bronchopulmonary dysplasia (BPD), are also associated with significant adverse neurologic effects such as reductions in myelination and abnormalities in neuroanatomical development. Ciclesonide (CIC) is a sGC prodrug approved for asthma treatment that exhibits limited systemic side effects. Carboxylesterases enriched in the lower airways convert CIC to the glucocorticoid receptor (GR) agonist des-CIC. We therefore examined whether CIC would likewise activate GR in neonatal lung but have limited adverse extra-pulmonary effects, particularly in the developing brain. Neonatal rats were administered subcutaneous injections of CIC, DEX or vehicle from postnatal days 1-5 (PND1-PND5). Systemic effects linked to DEX exposure, including reduced body and brain weight, were not observed in CIC treated neonates. Furthermore, CIC did not trigger the long-lasting reduction in myelin basic protein expression in the cerebral cortex nor cerebellar size caused by neonatal DEX exposure. Conversely, DEX and CIC were both effective at inducing the expression of select GR target genes in neonatal lung, including those implicated in lung-protective and anti-inflammatory effects. Thus, CIC is a promising, novel candidate drug to treat or prevent BPD in neonates given its activation of GR in neonatal lung and limited adverse neurodevelopmental effects. Furthermore, since sGCs such as DEX administered to pregnant women in pre-term labor can adversely affect fetal brain development, the neurological-sparing properties of CIC, make it an attractive alternative for DEX to treat pregnant women severely ill with respiratory illness, such as with asthma exacerbations or COVID-19 infections | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Bronchopulmonary dysplasia | |
| 650 | 4 | |a Ciclesonide | |
| 650 | 4 | |a Dexamethasone | |
| 650 | 4 | |a Glucocorticoids | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Glucocorticoids |2 NLM | |
| 650 | 7 | |a Myelin Basic Protein |2 NLM | |
| 650 | 7 | |a Pregnenediones |2 NLM | |
| 650 | 7 | |a Prodrugs |2 NLM | |
| 650 | 7 | |a Receptors, Glucocorticoid |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 650 | 7 | |a ciclesonide |2 NLM | |
| 650 | 7 | |a S59502J185 |2 NLM | |
| 700 | 1 | |a Franks, Alexis L |e verfasserin |4 aut | |
| 700 | 1 | |a Bargerstock, Erin M |e verfasserin |4 aut | |
| 700 | 1 | |a Kisanga, Edwina Philip |e verfasserin |4 aut | |
| 700 | 1 | |a Menden, Heather L |e verfasserin |4 aut | |
| 700 | 1 | |a Ghersi, Alexis |e verfasserin |4 aut | |
| 700 | 1 | |a Omar, Mahmoud |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Rudine, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Short, Kelly L |e verfasserin |4 aut | |
| 700 | 1 | |a Silswal, Neerupama |e verfasserin |4 aut | |
| 700 | 1 | |a Cole, Timothy J |e verfasserin |4 aut | |
| 700 | 1 | |a Sampath, Venkatesh |e verfasserin |4 aut | |
| 700 | 1 | |a Monaghan-Nichols, A Paula |e verfasserin |4 aut | |
| 700 | 1 | |a DeFranco, Donald B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurobiology of disease |d 1997 |g 156(2021) vom: 01. Aug., Seite 105422 |w (DE-627)NLM089461223 |x 1095-953X |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2021 |g day:01 |g month:08 |g pages:105422 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nbd.2021.105422 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2021 |b 01 |c 08 |h 105422 | ||